Ultra-Sensitive Platform for Nucleic acid detection using a novel method, Scanning Digital polymerase chain reaction (PCR)
A method for analyzing a target nucleic acid includes diluting nucleic acid targets and filling pico to femto-liter sized wells such that they contain a single target nucleic acid and one or more amplification reagents, amplifying the target in the individual wells, distinguishing wells containing amplicon from the target and amplicon from a variant of the target generated by polymerase error by using two differently labeled-hybridization probes, one hybridizing to the target and one hybridizing to a specific variant of the target; and analyzing target amplicons.
This application claims priority to U.S. Prov. Pat. Appl. No. 62/584,055 filed Nov. 9, 2017, the contents of which are hereby incorporated by reference as if fully set forth herein.
BRIEF DESCRIPTION OF THE DRAWING FIGURESPreferred and alternative embodiments of the present invention are described in detail below with reference to the following drawing figures.
There is a clear need in biological related sciences to determine the presence of low abundance nucleic acid sequences for gene expression analysis, mRNA analysis, vial load determination, and pathogen detection, among others. There is also a strong need in research for absolute quantification of target nucleic acid sequences. Absolute quantification is possible by partitioning a quantitative PCR reaction into 1 Os of thousands of individual femtoliter volumes, or wells. Each well contains a single target molecule (positive) or no target molecule (negative). Sample partitioning allows sensitive, specific detection of single template molecules. The partitioning mitigates the effects of target competition, making digital PCR amplification less susceptible to inhibition and greatly improving the discriminatory capacity of assays.
The only other currently available technology to perform absolute quantification of nucleic acid sequences (also known as Digital PCR) is to split the PCR reaction materials into thousands of individual emulsion droplets. This process is expensive, complicated, and cumbersome to perform and requires three separate instruments, a droplet generator, a thermocycler (for PC), and a flow-based droplet analyzer.
Embodiments include a novel structure and method for performing digital PCR using a low-cost, easy-to-use consumable and a combined thermocycler/analyzer. A PCR supermix is deposited into a slide containing approximately 20,000 microwells with volumes on the order of femtoliters. Capping layers, such as plastic or glass, are then added to seal each well to form individual reaction chambers for subsequent PCR.
Once prepared, the femtoliter well chips may be placed into a fully integrated system (it can also be done using two separate systems, one for PCR and one for the analysis) that performs the thermalcycling required for PCR and then the analysis. The system may comprise a laser with a beam focused to interrogate only one well at a time, at least one photodetector for measuring the emitted fluorescence from each individual well, a laser steering assembly for scanning the laser over the 20,000+ wells, and a programmable microcontroller. The system will also likely need to be able to “align” the laser to the consumable so that it “knows” where all of the wells are located. To do this, the preferred embodiment will be a photodiode placed on the opposite side (likely under) the femtoliter well consumable.
Additionally, there is a clear need in biological related sciences to determine the presence of low abundance nucleic acid sequences for gene expression analysis, mRNA analysis, vial load determination, and pathogen detection, among others. There is also a strong need in research for absolute quantification of target nucleic acid sequences. Absolute quantification is possible by partitioning a quantitative PCR into 10s of thousands of individual picoliter volumes, or wells. Each well contains a single target molecule (positive) or no target molecule (negative). Sample partitioning allows sensitive, specific detection of single template molecules (i.e., the molecule of interest). The partitioning mitigates the effects of target competition, making digital PCR amplification less susceptible to inhibition and greatly improving the discriminatory capacity of assays.
The only other currently available technology to perform absolute quantification of nucleic acid sequences (also known as Digital PCR) is to split the PCR reaction materials into thousands of individual emulsion droplets. This process is expensive, complicated, and cumbersome to perform and requires three separate instruments, a droplet generator, a thermocycler (for PC), and a flow-based droplet analyzer.
Embodiments include a structure and method for performing digital PCR using a low-cost, easy-to-use consumable and a combined thermocycler/analyzer. This is done by creating emulsion droplets using a low-cost, thin-film technology with an optional method to measure the size of the droplets, and to some extent, the contents of the droplets, just downstream of their production, all within the same structure/cassette. By combining precision laser processing and multi-layer laminates, an embodiment provides low-cost, high-efficiency emulsion droplet generating cassettes (see
Preferably, within the same cassette, it is also possible to incorporate a current Coulter-style particle interrogation structure (which may be described in one or more of U.S. Pat. Nos. 7,417,418, 7,515,268, 7,520,164, 7,579,823, 8,171,778, 8,329,437, and 8,804,105). When the optional Coulter orifice is added just downstream of the droplet fabricator, it is possible to measure the size of the particle using direct current (DC) and the contents of the droplet using simultaneous alternating current (AC). It is also feasible to use just DC or just AC current instead of both simultaneously.
An embodiment includes a system that works with the above described emulsion droplet generating cassette that will drive the droplet fabrication with Coulter orifice feedback to help control droplet size and (in some cases) single-cell encapsulation efficiency and/or determination. Control of droplet size, frequency, and efficiency can be accomplished by varying the applied pneumatic pressure and/or vacuum to the cassette. This system has the optional ability to perform the necessary thermal cycling to PRC on the prepared droplets when desired. This is done by thermally cycling the Retrieval Sample Well (
Alternate embodiments may include:
Instead of using the Coulter orifice for downstream QC and feedback, it is possible to run the sample through a flow cytometer immediately after fabrication to determine approximate droplet size and contents. This may be done with side-scatter (or forward light collection) and fluorescence.
The cassette could be simplified to have just the droplet orifice structure with no feedback.
One of the major challenges in forming droplets containing single cells, is the inability to control when a droplet should be formed such that it contains a desired cell. State of the art technologies use statistical models and cell concentrations to drive the efficiency of cell/droplets. Currently available commercial systems claim efficiencies of up to only 60%, and actual efficiencies can be much lower. Because the success of downstream single-cell sequencing operations depends on the success, efficiency, and purity, of correctly produced single-cell droplets, there is a strong market need for a highly efficient single-cell droplet generator that can produce droplets with desired cells (only) on demand. In addition, there are currently no commercially available droplet systems with built-in quality control checks of any kind.
An embodiment includes the multilayer thin-film droplet generator discussed above in Disclosure A with the addition of an epi fluorescence system to detect the presence of the cells of interest as they approach the droplet generating orifice. Also added is an electrical actuator (such as a piezoelectric actuator) capable of creating a transient pressure pulse to selectively force the desired cells through the droplet generating orifice, thereby only creating droplets containing cells, and driving efficiency towards 100%.
Cell/droplet efficiency, as well as purity (i.e., only desired cells and not debris) is absolutely critical as the success of downstream DNA sequencing operations relies heavily on both the percent efficiency and droplet purity. The best commercially available single-cell droplet systems have efficiencies approaching only 60%, and actual efficiencies are typically much lower.
Claims
1. A method for analyzing a target nucleic acid, the method comprising the steps of:
- diluting nucleic acid targets and filling pico to femto-liter sized wells such that they contain a single target nucleic acid and one or more amplification reagents;
- amplifying the target in the individual wells;
- distinguishing wells containing amplicon from the target and amplicon from a variant of the target generated by polymerase error by using two differently labeled-hybridization probes, one hybridizing to the target and one hybridizing to a specific variant of the target; and
- analyzing target amplicons.
2. The method according to claim 1, wherein said amplifying step is a polymerase chain reaction and the one or more amplification reagents includes one or more primer pairs.
3. The method according to claim 1, wherein said distinguishing step comprises scanning a laser across each well individually.
4. The method according to claim 1, wherein said analyzing step comprises detecting said amplicons by hybridization to detectably-labeled probes.
5. The method according to claim 1, wherein said analyzing step is conducted on amplicon from wells that were not distinguished in said distinguishing step.
6. The method according to claim 1, wherein said analyzing step comprises:
- determining a number of wells that contain only wild-type target;
- determining a number of wells that contain only a variant of the target.
7. The method according to claim 6, wherein presence of wells containing only said variant is indicative of a disease.
8. The method according to claim 7, wherein the disease is cancer.
9. The method according to claim 6, wherein the variant is an allelic variant.
10. The method according to claim 9, wherein the allelic variant is a single nucleotide polymorphism.
Type: Application
Filed: Nov 8, 2018
Publication Date: May 9, 2019
Inventors: Harold E. Ayliffe (Ketchum, ID), Donald O'Neil (Ketchum, ID)
Application Number: 16/184,863